Planta Med 2015; 81 - PW_17
DOI: 10.1055/s-0035-1565641

In vitro antileishmanial activity of Brazilian plant species

RC Paula 1, SM da Silva 1, F Frezard 2, KF Faria 1, PRV Campana 3, AF Silva 4, L Pieters 5, CG Silva 6, VL Almeida 3, 5
  • 1Laboratório de Bioensaios em Leishmania, ICBIM, Universidade Federal de Uberlândia, Uberlândia, Brazil
  • 2Departamento de Fisiologia e Biofísica, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
  • 3Serviço de Fitoquímica e Prospecção Farmacêutica, Fundação Ezequiel Dias, Belo Horizonte, Brazil
  • 4Empresa de Pesquisa Agropecuária de Minas Gerais, Belo Horizonte, Brazil
  • 5Natural Products & Food Research and Analysis (NatuRA), University of Antwerp, Antwerp, Belgium
  • 6Serviço de Biotecnologia Vegetal, Fundação Ezequiel Dias, Belo Horizonte, Brazil

Leishmaniasis is an infectious disease still widely spread in Brazil. It is a public health problem for the country due to its magnitude and geographic expansion leading to a complex, expensive and laborious control system [1, 2]. There is an urgent need to search for new medicines to treat leishmaniasis. Natural products can provide unlimited opportunities for the discovery of new lead compounds targeting this neglected disease. In this work, we investigated the antileishmanial activity of 22 plant extracts, from seven different species belonging to Apocynaceae, Asteraceae, Ebenaceae, Primulaceae and Rutaceae families. Samples were evaluated against promastigotes from L. infantum (strain BH46). The antileishmanial activity was measured 24h after exposition to the sample using the resazurin-based viability assay [3]. The toxicity of test samples is currently being investigated using dye exclusion method for cell viability using non-infected macrophages. According to preliminary results, four extracts from Aspidosperma spp. showed antileishmanial activity. The dichloromethane (DCM) extract from the stem showed an IC50 value of 89.5 ± 4.9 µg/mL. The IC50 of the remaining active extracts is currently being determined. The antileishmanial activity of this species will be further investigated, using intra- and extracellular parasite forms from other Leishmania species. The metabolic profiling and targeted isolation of bioactive constituents are in progress aiming for the identification of new lead compounds with antileishmanial activity.

Acknowledgement: To CNPq for the financial support to Dr. VL Almeida (ref. 249299/2013 – 5).

References:

[1] Gontijo M, Rev Bras Epidemiol 2004; 7: 338 – 349

[2] Rocha et al., Phytomedicine 2005; 12: 514 – 535

[3] Corral et al., J Microbiol Methods 2013; 94: 111 – 116